BioSpace News Archive

Quest Diagnostics (NYSE: DGX), today announced that it has received a score of 100% on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

According to the World Health Organization (WHO), breast cancer is the most common type of cancer diagnosed in women around the world, and approximately 2.1 million women are diagnosed with the disease each year.

Cerebral palsy refers to a group of disorders that impede a person’s ability to walk or move and maintain physical balance. One of the most common motor disabilities, cerebral palsy is a congenital disorder generally caused by abnormal brain development before birth.

NeurologyLive®, has partnered with the Consortium of Multiple Sclerosis Centers (CMSC) on an exclusive, expert-led Peer Exchange discussion covering the latest research and clinical implications of Epstein-Barr virus (EBV) infection and multiple sclerosis (MS).

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the closing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,725,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”).

AHF welcomed news that Moderna, maker of a widely deployed mRNA COVID-19 vaccine, started an early-stage clinical trial yesterday on a potential HIV vaccine that utilizes the same mRNA technology as in its successful COVID-19 vaccines.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its interim financial results for the three month period ended November 30, 2021.

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody library and discovery tools, announced the publication of two peer-reviewed articles describing its Generation 3 Antibody Discovery Platform.

HanBio Therapeutics, a biotechnology company committed to researching and developing next generation transformative medicines, announced that it has completed a US$40 million Series A financing to advance the preclinical and clinical development of its series of innovative antibodies and other biologics products.

Leading China -based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC).